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Abstract: 
Cortical spreading depolarisation (CSD) is an emerging mode of secondary 
neuronal damage in acute brain injury (ABI). Subsequent repolarisation is a 
metabolic process requiring glucose. Instances of CSD and glucose 
derangement are both linked to poor neurological outcome, but their causal inter-
relationship is not fully defined. This systematic review seeks to evaluate the 
available human evidence studying CSD and glucose to further understand their 
dynamic relationship. We conducted a systematic review of studies examining 
CSD through electrocorticography and cerebral/systemic glucose concentrations 
in ABI, excluding animal studies. The search yielded 478 articles, of which 13 
were eligible. Across 10 manuscripts, 125 patients received simultaneous 
monitoring, with 1,987 CSD episodes observed. 8/10 studies observed 
correlation between CSD and glucose change. 7/8 studies observed possible 
cumulative effect of recurrent CSD on glucose derangement and two identified 
correlation between glycopenia and incidence of CSD. These findings confirm a 
relationship between CSD and glucose, and suggest it may be cyclical, where 
CSD causes local glycopenia, which may potentiate further CSD. Positive 
observations were not common to all studies, likely due to differing methodology 
or heterogeneity in CSD propensity. Further study is required to delineate the 
 
 
utility of the clinical modulation of serum and cerebral glucose to alter the 
propensity for CSD following brain injury. 
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Introduction: 
Rationale: 
Cortical spreading depolarisation (CSD) is a pathophysiology of secondary injury 
in a variety of cerebral insults, with emerging recognition of its importance.1 CSD 
is typically described as a pathological wave of neuronal and glial depolarisation 
which is self-propagating, and spreads throughout cerebral tissue at a rate of 2-
5mm/min, with consequent severe disturbance of local ionic gradients.2 This can 
lead to a local energetic-failure mediated abolition of cortical activity known as 
cortical spreading depression. Since the discovery of cortical spreading 
depression in 1944,3 the involvement of CSD in the aetiology of migraine has 
been well described,4 with its first observed description in human brain injury5 in 
2002. 
Since then CSD has been increasingly recognised as a factor in the exacerbation 
of cellular injury after brain injury. The incidence of CSD has been observed in 
humans with multiple modalities of acute brain injury (ABI); traumatic brain injury 
(TBI), subarachnoid haemorrhage (SAH), intracerebral haemorrhage (ICH) and 
occlusive ischaemic stroke.6–11 In addition to representing a widespread 
phenomenon, the incidence of CSD has been linked to unfavourable neurological 
outcome in TBI.7 
 
 
To re-establish physiological ion gradients after CSD there is supraphysiological 
tissue metabolic demand and therefore glucose requirement.12 Animal studies 
have demonstrated that deranged cerebral glucose can alter the susceptibility of 
neural tissue for the initiation of CSD.13,14 As such there are grounds for 
considering glucose derangement as both a precipitant and consequence of 
CSD. 
It is well established that deranged cerebral and systemic glucose levels correlate 
with poor neurological outcome and increased mortality.15–17 As such, glucose 
control is a prominent component of the clinical management of ABI in the 
neurocritical care setting. The mechanism by which deranged cerebral glucose 
metabolism worsens outcomes after brain injury is not fully understood, but 
appears to be independent of ischaemia.18 To what extent the relationship 
between glucose and CSD is involved in this mechanism is also not understood. 
CSD has been demonstrated to be a widespread phenomenon in ABI and to 
correlate with outcome,6–11 so CSD represents an important potential target for 
therapeutics in preventing secondary injury. Glucose is a key player in the 
physiology of CSD, with its derangement also associated with secondary injury. 
Whilst research into the clinical prevention of the incidence of CSD continues, 
glucose derangement has established methods for treatment in clinical practice. 
Therefore defining the relationship between glucose and CSD is a worthy subject 
 
 
of further understanding, which at present has conflict in its small body of 
evidence. It is unclear if glucose derangement represents: a factor in initiating 
CSD, a consequence of CSD, neither, or both - in a self-perpetuating cycle of 
supply and demand mismatch. As such the aim of this systematic review is to 
collate and evaluate the evidence examining glucose and CSD in the context of 
ABI and its composite pathologies, to further understand their complex 
relationship. 
 
Objectives: 
Our objective is to systematically evaluate the available literature examining the 
correlation between glucose derangement and CSD in humans. Specifically, we 
seek to summarise the available evidence for: (1) the effects of CSD on 
extracellular glucose concentration; and (2) the presence of deranged glucose 
concentrations as a risk factor for CSD. 
 
 
 
 
 
 
Materials and methods: 
A systematic review of the literature was performed following the methodology of 
the Cochrane Handbook for Systematic Reviewers,19 and presented in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA).20 
The review questions determined by the primary author (AS) in conjunction with 
the lead researcher (AE) were: 
(1) Is electrocorticographic (ECoG) evidence of CSD associated with subsequent 
changes to cerebral extracellular glucose levels, and does the incidence of CSD 
correlate with sustained glucose changes? 
(2) Is there evidence of a cumulative effect of recurrent CSD as identified by 
ECoG on cerebral extracellular glucose levels? 
(3) Does the incidence of CSD demonstrated on ECoG have an association with 
preceding or baseline glucose levels (cerebral or systemic)? 
 
 
 
 
 
 
Inclusion Criteria: 
Population: 
The population of interest were human subjects with any of the following 
conditions: TBI, SAH, ICH or ischaemic occlusive stroke. 
 
Outcome measures: 
The outcome measures of interest were: ECoG monitoring evidence of cortical 
spreading depolarisation; and local (i.e. cerebral extracellular fluid) or systemic 
(i.e. serum) glucose concentration measures. Secondary outcomes considered 
were results of analysis of the relationship between the incidence of CSD and 
local/systemic glucose concentration. 
 
Setting: 
Given the intensive monitoring required to gain the above data such studies 
would be in the intensive care unit or neurosciences critical care settings.  
 
 
 
 
Methodology: 
Any research methodology in humans was considered for inclusion, including 
observational studies and case series/reports. 
 
Exclusion Criteria: 
Studies conducted in animal models or in vitro human models were excluded. 
Studies which recorded the variables of interest, but did not report sufficient data 
on these variables for our research questions were also excluded. 
 
Information Sources: 
We systematically searched the following databases, from their respective 
inception to December 2017: Medline, Embase, Cochrane Central, NICE 
Evidence and Web of Science. Reference lists of pertinent narrative review 
articles on the topic were hand-searched for suitable articles. See appendix 1 for 
an example of search strategy. 
 
 
 
 
Study Selection: 
Studies were independently screened for inclusion by two reviewers, AS and IN, 
utilising a referential standardised proforma. Eligibility for study inclusion was 
defined as: a study of human patients with ABI, with the measurement of 
incidence of cortical spreading depolarisation and local/systemic glucose levels, 
with subsequent analysis of the relationship. 
 
Data Extraction: 
Data were extracted from included reports by two reviewers: AS and IN, 
conducted independently in duplicate, using piloted forms. Data extracted 
included; study characteristics, patient demographics, number of patients, ECoG 
variables (proximity to primary lesion, frequency), microdialysis variables 
(sampling rate, proximity to ECoG device) and results and conclusions of 
comparative analysis. 
 
Risk of Bias in Individual Studies: 
Two reviewers (AS, IN) assessed the risk of bias of each individual study using 
the RTI item bank,21 with discrepancies discussed with a third party (AE). 
 
 
Synthesis of Results: 
The heterogeneous nature of data collection and analysis methods precludes our 
ability to combine and synthesise results. As such a qualitative narrative summary 
will be presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: 
Study Selection: 
A search for literature pertaining to both CSD and glucose in the context of human 
ABI yielded 478 articles. After removal of duplicates, 337 titles with abstracts were 
screened against the inclusion criteria. 31 full text articles were obtained for 
eligibility assessment, of which 13 studies were included (Figure 1). Of the eligible 
articles, 10 original articles were included in the full qualitative review (Table 1). 
The further three eligible articles were short conference proceedings or abstracts, 
and are considered briefly in (Table 2). All manuscripts screened for inclusion 
were available in English. [Insert Figure 1] 
 
Study and Patient Demographics: 
Of the 13 articles eligible for inclusion,11,22–33 10 were published manuscripts11,22–
30 and three were abstract publications from meetings (poster presentations).31–
33 11 studies were observational,22,24–33 of which; seven were identifiable as 
prospective,22,24–27,29,30 two were mixed prospective/retrospective28,32 and two 
reported insufficient methodology for discernible classification.31,33 Two studies 
were single-patient case studies.11,23 
 
 
All studies recruited only patients with clinical indication for a neurosurgical 
procedure (craniotomy, craniectomy or burr hole) for ABI. Four studies recruited 
only TBI patients,23,24,31,32 two recruited only SAH patients,28,29 two recruited only 
ICH patients11,26 and one study recruited only patients with ischaemic stroke.30 
The remainder recruited patients with any aetiology of ABI from the above (TBI, 
SAH, ICH, ischaemic stroke)25,27,33 with the exception of one study which 
recruited only patients with TBI, SAH or ICH.22 
Of the 13 included articles, all identified CSD by a subdural electrocorticography 
strip. All articles measured local glucose via cerebral microdialysis (CMD), except 
for one study which examined serum glucose alone.32 
Of the observational studies published as full articles, six studies recruited only 
patients with an admission Glasgow Coma Score (GCS) of greater than 4,22,25–29 
and six studies excluded patients with bilaterally fixed and dilated pupils.22,24,25,27–
29 Three studies excluded patients with a history of significant trauma or bleeding 
less than five days prior to admission.25,28,29 One study did not describe any 
exclusion criteria.30 
Across manuscripts included (Table 1), 125 patients in total were studied, with a 
mean of 15.6 patients per study, ranging from 10 to 24 (excluding single patient 
case studies). Mean age was 47.6 years (range 18 to 72). Of studies reporting 
 
 
patient gender, 56.8% were male: two studies did not report gender distribution 
of their patients.25,27 A total of 1,987 episodes of CSD were observed across 
these studies. Total monitoring time varied between studies, with mean 
monitoring durations ranging from 67 to 210 hours. Time from injury to 
recruitment ranged from within 24 hours to within five days. 
 
Monitoring Techniques: 
Abstracts from meetings, owing to publication modality, did not report sufficient 
information on their monitoring techniques for inclusion here. As such the 
following subsections pertain only to the studies with full manuscripts. 
 
Electrocorticography Monitoring Techniques: 
All 10 studies (Table 1) utilised a six or eight electrode electrocorticography 
device (Wyler/Ad-Tech) inserted during clinically indicated neurosurgical 
intervention. Positioning of the electrodes was variable: four studies reported the 
electrode was placed on the cortex alone,23,26,28,29 and seven studies reported 
positioning the electrode specifically on the cortex overlying peri-infarct or peri-
contusional tissue.11,22,24,25,27,30 One study utilised intraoperative laser speckle 
 
 
imaging to identify the infarct rim for placement.30 Four studies recognised and 
utilised subclassification of CSD in their interpretation of ECoG data.25,26,28,30 In 
identified prospective observational studies, the range of patients with recorded 
episodes of CSD is between 38% and 90% (72% mean) across all brain injury 
subtypes. 
 
Glucose Monitoring Techniques: 
All 10 studies utilised a CMA cerebral microdialysis device, inserted during 
clinically indicated neurosurgical intervention. All studies reported insertion of the 
microdialysis probe with sufficient detail to describe its proximity to the lesion or 
neural tissue of interest, with one exception.28 Three studies utilised an online 
assay through rapid sampling microdialysis (rsMD), with a reported sampling 
interval of 30 to 60 seconds,22,26,27 whilst the remaining studies utilised an 
intermittent offline sampling technique at 60 minute intervals. These were 
analysed immediately at the bedside with the exception of two studies which 
either refrigerated23 or froze24 samples for later analysis. 
 
 
 
 
Device Proximity: 
With one exception,28 all studies reported proximity between the ECoG and CMD 
devices. Three studies reported prospective aims of specific distances: within 
1cm,24 1-1.5cm22 or 1-2cm23. One study utilised two CMD probes, 5mm and 
15mm from the infarct rim with the ECoG strip overlying both probes.30 One study 
prospectively aimed for the devices to be qualitatively “as near as possible” and 
recorded proximity on post-operative imaging studies,27 whilst other studies did 
not report techniques to confirm position. This imaging approach recognised that 
in one patient the distance between devices was 8cm. The remaining studies 
reported proximity of placement as: in corresponding parenchyma,25 “usually 
sited on same gyrus”,26 “regional”11 or “close”.29 
 
Results of Individual Studies: 
Given the heterogeneity of the considered studies, particularly when considering 
their analytical methods, the studies with their key findings are summarised in 
Tables 1 and 2, with their results further displayed in Table 3. 
 
 
 
 
Qualitative Narrative: 
Whilst heterogenous data generated across these studies has rendered 
quantitative summary of data futile, the studies will here be discussed with 
relevance to the each of the questions posed by this review. Table 3 gives a brief 
overview. Given the variety of study size and considered pathologies, brief details 
of n number and pathology/distribution of pathology are included in the narrative 
for ease of reference. Greater detail is given in Table 1.  
 
Evidence of correlation: 
Studies reporting a positive correlation included 70% of the total patients across 
all studies (88 of 125). Of the 10 manuscripts included, all describe observation 
of correlation between ECoG findings of depolarisation and deranged glucose 
concentration, with the exception of two studies.24,29 Hinzman et al24 (16 patients 
with TBI) determined no correlation through their analysis, using a control of daily 
glucose values from the cohort of patients without CSD, against which daily 
glucose values of patients with CSD were compared. 83% of glucose values 
overall were low (<1mmol/L). Also showing no correlation, Sarrafzadeh et al29 (21 
SAH patients) took hourly glucose concentrations and established a control 
concentration through local regression with locally weighted scatter-plot 
 
 
smoothing (LOWESS) regression to deal with irregular sampling. Glucose 
concentrations (median levels 1.48mmol (0.00-8.79 range)) at time points of CSD 
episodes were then compared with expected levels on the LOWESS 
interpolations.  
 
Glucose as a metabolic “signature” of spreading depolarisation: 
Of three studies utilising rsMD with continuous online assay,22,26,27 two 
demonstrated consistent and significant falls in cerebral glucose occurring during 
or shortly after CSD22,27 – a phenomenon termed the metabolic “signature”. 
Overall, four studies including 51 patients observed a metabolic “signature”, and 
three studies including 46 patients did not. 
Feuerstein et al22 recruited 10 patients with ABI (TBI n=5, ICH n=3, SAH n=2), 
and using rsMD compared epochs of glucose values five minutes before CSD 
with values five and 20 minutes after CSD. They used the area under the curve 
(AUC) of microdialysis concentration changes and subsequent two-tailed 
Wilcoxon signed-rank test, finding that 90 glucose AUCs were significantly 
different from zero (p<0.0001) with no significant difference seen in patients 
without CSD. This demonstrates a consistent and significant fall in glucose in the 
five to 20 minutes after episodes of CSD. 
 
 
A “signature” fall in glucose after CSD was also identified using rsMD by Rogers 
et al27. The study, with a cohort of six patients (TBI n=3, ICH n=1, SAH n=1, 
ischaemic stroke n=1) observed 18 CSD episodes, experiencing technical 
difficulties with ECoG monitoring, reducing the quantity of data available for 
interpretation. This study compares peak glucose derangement during or after 
CSD with a baseline prior to onset, showing by Wilcoxon signed-rank test that 
glucose fell significantly during or after all observed events (p<0.01). O’Phelan et 
al31 corroborate these observations in their cohort of four patients with TBI: this 
study abstract reports 50% of CSD events were associated with a fall in glucose, 
(exploratory data analysis), as observed using intermittent dialysis techniques. 
In contrast, Parkin et al26 utilised rsMD in 11 patients with ICH. This did not 
identify a “signature” glucose fall – patterns of dialysate glucose change were 
classified into transient increase, transient decrease, biphasic change or 
oscillation. No single pattern was observed as the typical response through 
exploratory data analysis, though no statistical analysis was performed.  
Six further studies examined the glucose response to CSD using intermittent 
hourly cerebral glucose values. The utility of hourly glucose sampling is 
significantly limited for investigating the dynamics of a phenomenon occurring 
over 10 minutes. As such, the results of studies utilising this methodology are not 
considered in this section. 
 
 
Prolonged glucose derangement after spreading depolarisation: 
Beyond the immediate metabolic “signature”, we examine whether any glucose 
change in association with an episode of CSD was sustained for a considerable 
period. To consider this as a distinct finding from the metabolic “signature”, we 
identified studies commenting on intervals specifically greater than 10 minutes 
after CSD events, where the CMD collection interval does not include the CSD 
event itself. 
Feuerstein et al22 (TBI n=5, ICH n=3, SAH n=2) found that at 20 minutes after 
CSD events there was not recovery in dialysate glucose to the pre-CSD baseline, 
with sustained glucose changes of -32 µmol/L (Wilcoxon signed-rank test, 
p<0.0001), with longer CSD duration correlating with greater glucose decreases 
(Pearson product-moment correlation, r=-0.25, p=0.05). 
Parkin et al26 (ICH n=11) used rsMD, analysing glucose values between 60 and 
120 minutes after the last CSD episode, against a control value calculated over 
a 60 minute period in the second hour of the monitoring period. This found 
glucose change over the monitoring interval strongly correlated with the number 
of CSD occurrences (r2=0.76, p=0.0004), with the suggestion that “each 
spreading event leads to on average a 0.11mmol/L decrease in glucose”. It is 
unclear however if this corresponds with a true effect of sustained change in 
 
 
glucose concentration. Notably, initial glucose levels ranged from 0.19mmol/L to 
1.6mmol/L, with the range at the end of the recording period between 0.02mmol/L 
and 1.4mmol/L. 
Rogers et al27 (TBI n=3, ICH n=1, SAH n=1, ischaemic stroke n=1) observed on 
one occasion that glucose levels 10 minutes post-CSD had not returned to 
baseline concentration, though this was not reported to be consistent in their 
exploratory data analysis. As with the consideration of the metabolic “signature”, 
the results of studies utilising intermittent hourly glucose sampling will not be 
discussed here: this rate of sampling would be of little use in observing the 
duration of effect of CSD on glucose with sufficient accuracy. 
 
Cumulative effect of recurrent spreading depolarisation on glucose:  
Here we report results of studies which examined the effect of multiple CSD 
episodes on glucose. Of the studies examining this relationship, three studies 
including a total of 45 patients demonstrated direct evidence of cumulative 
effect,22,28,30 whilst across four further studies, 42 patients demonstrated possible 
evidence.23,25–27  
Results amongst these studies were divided: three studies reported significant 
glucose concentration decreases but only in the context of clustered CSD, not in 
 
 
single non-recurring episodes.11,28,30 (Schiefeker et al,11 ICH n=1; Sakowitz et 
al,28 SAH n=17; Pinczolits et al,30 ischaemic stroke, n=18).  Fabricius et al33 also 
found a correlation between clusters of CSD and decreasing glucose, 
communicated in their study abstract (n=220, pathology distribution not reported, 
r2 and p value not reported). Three further studies did not identify a glucose fall 
after CSD, though it is noteworthy that these studies did not report sub-
classification of CSD events nor did they distinguish clustered CSD23,25,29. 
(Hartings et al,23 TBI n=1; Krajewski et al,25 n=24 (TBI n=3, ICH n=1, SAH n=17, 
ischaemic stroke n=3); Sarrafzadeh et al,29 SAH, n=21). 
Feuerstein et al22 (TBI n=5, ICH n=3, SAH n=2) observed consistently that where 
a second CSD episode occurred within 50 minutes, glucose concentrations had 
not recovered to baseline levels and progressively fell with subsequent episodes. 
Two studies28,30 found glucose only decreased significantly in clustered CSD, 
discussed above, which evidences a cumulative effect eliciting a greater 
response in glucose derangement. 
Further studies found possible evidence of this phenomenon: Parkin et al26 
observed strongly significant correlation between ECoG events and a greater 
decrease in dialysate glucose levels in 11 patients with ICH (r2=0.76, p=0.0004). 
This study result is unable to draw conclusions on the cause-effect nature of this 
relationship.  
 
 
In the TBI case study monitored by Hartings et al,23 exploratory data analysis 
demonstrated multiple clustered CSD coinciding with an episode of low cerebral 
glucose levels. Rogers et al27 (TBI n=3, ICH n=1, SAH n=1, ischaemic stroke 
n=1) observed a single episode of CSD where baseline dialysate glucose was 
“low” (100µM), and then fell to “critically low” levels (20µM) after CSD. This low 
baseline is not reported as being in the context of a shortly preceding CSD and 
so does not demonstrate “cumulative effect” as such, though it does observe that 
low cerebral glucose can be lowered further by CSD episodes, in this instance to 
a critical level of depletion.  
 
Effect of glucose derangement on propensity for spreading depolarisation: 
Here we review the evidence of glucose derangement as a causative factor for 
incidence of CSD. Two studies (35 patients) found a statistically significant 
correlation between glucose derangement and CSD incidence across the entire 
recording interval.25,26 Krajewski et al demonstrate evidence that deranged 
cerebral glucose may increase the incidence of CSD:  cerebral glucose outside 
the range of 1-3mM was present more frequently 20 minutes prior to CSD, 
compared with 20 minutes after (p<0.05). 
 
 
Parkin et al26 (ICH n=11), reported correlation between glucose depletion over 
the entire study interval and incidence of CSD events (r2=0.76, p=0.0004). 
However, number of transient glucose derangements did not correlate with CSD 
events (r2 and p values not given). 
Two studies, with a total of 37 patients, did not find evidence of this relationship 
through their analysis.24,29 Hinzman et al24 (TBI n=16) found that the subgroup 
with CSD had no difference in daily glucose dialysate levels to those without (two-
way ANOVA with post-hoc Bonferroni, p>0.05), in the context of 83% of all 
dialysate glucose levels in this study being low (<1mmol/l). Sarrafzadeh et al,29 
in their cohort of 21 patients with SAH, found that CSD was not linked to local 
deviations from their LOWESS curve of cerebral glucose, concluding that this 
confirms that cerebral glucose derangement does not increase incidence of CSD. 
The methodological approach resulting in probable data homogenisation of both 
these studies has been discussed above. Few studies reported results of serum 
glucose concentration in relation to CSD; these are reported in Appendix 2.  
 
Risk of Bias: 
Study bias was assessed by an adapted RTI item bank for observational 
studies21, with the results displayed in Table 4. Overall, there were possible 
 
 
sources of bias identified in statistical methods, inconsistencies or lack of 
reporting on monitoring techniques, and study design. Despite the potential for 
bias, the results were deemed to be believable in nine of 10 studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion: 
Summary of Evidence:  
Correlating glucose & spreading depolarisation: 
Eight of 10 studies (88 of 125 patients) reported correlation between CSD events 
and glucose derangement, supporting the existence of a true relationship. The 
two studies (37 of 125 patients) with negative findings24,29 have used contrasting 
analytical methodologies to the other studies, with one24 reporting a high 
preponderance of low glucose levels across the cohort (83%), with the possible 
effect of obfuscating the observation of a relationship. 
 
The metabolic “signature”: 
High resolution studies analysing short “signature” windows after CSD have 
yielded consistent observation of the metabolic “signature”. Two of three 
studies22,27 using high resolution rsMD identified consistent and statistically 
significant evidence of glucose decrease (~0.2 mM (p=0.01),27 43.4 µmol/L 
(p=0.05)22)  in the minutes after episodes of CSD. The third rsMD study26 did not 
examine the immediate “signature” window, but rather analysed a period 60 to 
120 minutes after CSD.  
 
 
Sampling frequency will affect the ability to detect glucose change; the rate of 
change of glucose – particularly in the response to CSD – occurs in a time interval 
considerably less than the 60 minute sampling interval utilised in several included 
studies. Principles of sampling frequency for continuous functions stipulate that 
a function with bandwidth B require a sampling frequency of 2B, i.e. the Nyquist 
rate.34 As such, the results of low resolution studies cannot be considered in 
observation of the metabolic “signature”. 
 
Prolonged effects on glucose: 
The true duration of the metabolic effect of CSD seems to be variable, both 
between and within the considered studies. Given the range of durations within 
studies, and even within patients, it seems likely that the duration of relative local 
glycopenia is dependent on a number of factors. For example, findings in included 
studies have demonstrated continued glycopenia between 10 to 120 minutes 
post-CSD. This is in contrast to the descriptions of a metabolic “signature” which 
were relatively homogenous, occurring either during or within minutes of CSD. 
If we presume the metabolic demand of repolarisation a constant, variability in 
duration of effect would logically be dependent on supply - the physiological 
variables here would include serum glucose concentrations and CBF. Of course 
 
 
this is an oversimplification; CSD are not a uniform phenomenon, neither in 
number, duration nor extent of tissue to which they spread. For example, 
Feuerstein et al observed overall significantly sustained glucose changes after 
CSD of -32 µmol/L (p<0.0001), but that longer suppression by CSD led to a 
greater fall in dialysate glucose, thus increasing the demand with inevitable 
effects on the recovery interval.22 Further complicating the phenomenon, the 
incidence of CSD influences regional CBF (rCBF) which may contribute to the 
variability of the glucose decrease observed. The normal haemodynamic 
response is of regional hyperperfusion to match metabolic demand. This is a 
physiological phenomenon of normal neurovascular coupling, which is followed 
by a period of regional hypoperfusion termed ‘spreading oligaemia’. However, 
CSD episodes in the context of disturbed microvascular reactivity have been 
shown to cause an inverse haemodynamic response, with early 
vasoconstriction2,35,36 paradoxically inducing further compromise to metabolically 
challenged tissue, termed ‘cortical spreading ischaemia’. This concept has been 
comprehensively reviewed elsewhere.36,37 
 
Cumulative CSD and glycopenia: 
 
 
In support of the cumulative effect model, studies using intermittent CMD 
sampling techniques only identified significance in glucose derangement where 
clusters of CSD had occurred. Amongst studies using low-resolution CMD 
techniques, three studies recognised clustered CSD separately finding a glucose 
fall after these episodes.11,28,30  
More directly, CSDs recurring within 50 minutes of each other were observed to 
create a cumulative effect on glucose, whereby the glucose reduction of a second 
CSD is seen before the metabolic recovery from the first.22 We have also seen 
that when glucose is at a low baseline, CSD occurrence can reduce this to critical 
levels (as low as 20µM), illustrating that CSD can deplete glucose to the point of 
metabolic crisis, offering a mechanism of neural damage as a direct consequence 
of CSD. Again this effect has been inconsistently observed, suggesting variation 
dependent on other factors. 
 
Does glycopenia cause CSD? 
The evidence seen in this review in relation to glucose derangement as a 
precipitant of CSD is minimal. Cerebral glucose derangement correlates with 
incidence of CSD, but this alone is insufficient to clarify cause-effect. More 
significant here is the correlation of deranged cerebral glucose (e.c. outside the 
 
 
range of 1-3 mM)  observed as significantly present 20 minutes prior to CSD by 
Krajewski et al.25 This is more supportive of glucose derangement also as a 
precipitant, and not only as a consequence. Similarly, Krajewski et al25 correlate 
serum glucose derangement with CSD, though its temporal relationship with 
cerebral glucose levels was not examined. Previous commentary on the role of 
insulin therapy to target tight serum glucose control in TBI has outlined the risk of 
serum glucose modulation on cerebral glucose levels, with the description of a 
case of absolute cerebral glycopenia in a patient with TBI receiving insulin 
therapy.38 As such, serum glucose levels are of clear relevance in the relationship 
between cerebral glucose and CSD, and further consideration is indicated for 
future studies. Given the unclear optimal target for glycaemic control, particularly 
in TBI,39 further understanding of how this affects CSD incidence would be of 
benefit to ongoing work examining control of serum glucose concentrations.  For 
comprehensive results reporting and further discussion on serum glucose and 
CSD, see Appendix 2. 
Glucose derangement as a precipitant of CSD would likely have a dose-response 
relationship, alongside interactions with other physiological variables. Included 
studies have observed high CSD incidence coinciding with deranged cerebral 
glucose. This may represent glucose derangement perpetuating CSD. Mild to 
moderate glycopenia may be well compensated for, where serum 
 
 
normoglycaemia coupled with normal CBF facilitates adequate glucose provision. 
Where this does not occur, continuation of this metabolic spiral downward would 
lead to non-ischaemic cell death. Extracellular metabolite levels can then 
equilibrate with serum and no longer be subject to the metabolic demands of 
viable tissue. As such, in the rare circumstances of this phenomenon occurring, 
the temporal window to observe it is narrow. Experimental animal models13,40 
have illustrated higher incidence of CSD in glucose depletion, though this is more 
complex to show conclusively in observational human studies. 
 
 
 
A cyclical relationship? 
From the qualitative accumulation of these studies, we offer a possible sequence 
of events: (1) episode of CSD; (2) reduction in local tissue glucose, which may 
be sustained; (3) reduction in local threshold for further CSD; (4) dependent on 
other factors, further CSD may or may not occur. (5) This sequence then could 
potentially continue, with contributory influence of other physiological 
derangement (beyond the scope of this review), until either: (a) physiological 
factors normalise and CSD threshold rises, or (b) critical glucose depletion 
 
 
occurs, resulting in neural damage. Once the neural tissue is damaged 
sufficiently, its ability to de- and re-polarise will cease and the relationship is no 
longer observed. Possible causative relationships are suggested in Figure 2. 
[Insert Figure 2] 
 
Study limitations: 
Whilst comprehensive in its search, the available evidence for this review is 
limited. To maximise studies available for consideration, our inclusion criteria 
includes all ABI. A number of included studies, as does this review, consider ABI 
as a single disease, whereas the reality is several discrete pathologies, possibly 
with discrete relationships between CSD and metabolism. As summarised in 
Table 3, there is no clear relationship between considered pathology and study 
outcome. However, it remains likely that considering ABI homogeneously will 
dilute the accuracy of the results, given the distinct possibility of idiosyncratic 
CSD-metabolism relationships between the differing modalities of cellular injury.  
Study groups have employed varying methodology and analytical techniques, 
which has led to heterogeneous result reporting. As such this review was unable 
to perform statistical meta-analysis. Each study has collected largely similar data, 
with the exception of CMD sampling intervals, but the interpretation methods and 
 
 
statistical models used have differed greatly. This is likely a reflection of the 
generalised aims of the studies captured, which mostly aimed to “study the 
metabolic dynamics of CSD” or similar. This lends itself to a broad interpretation 
of what appropriate statistical methods might be employed to establish the 
significance of any observed relationship.  
The reporting of baseline glucose levels by the included works has been variable. 
It is likely that if baseline glucose levels are low throughout a study cohort, 
detecting significant change in concentrations would be less likely, particularly 
where combined with intermittent sampling methodology. Such “floor effects” 
have the potential to obfuscate any observable relationship, but we have been 
unable to account for this given the variability in reporting. 
Our study questions are deliberately of limited scope, in order closely examine 
this important relationship, but in doing so we do not investigate the wider context 
of other physiological factors.  
 
Other factors: 
Besides some consideration of the effect of serum glucose,25 included studies 
have not accounted for other variables with the potential to influence either CSD 
or cerebral glucose. For example, CBF alone is a potential confounder for both 
 
 
variables of interest; increased probability of CSD has been demonstrated as a 
function of decreasing cerebral perfusion pressure (CPP),41 and would also 
decrease glucose delivery. Lactate has been frequently considered, but cerebral 
oxygen availability will also have considerable metabolic effects which may 
obfuscate the observed relationship between glucose and CSD. For further 
discussion on lactate and CSD, see Appendix 3. 
Methodological differences may account for inter-study variability, and patient / 
monitoring placement differences may account for intra-study variability. 
However, even intra-patient variability in the CSD-glucose dynamic has been 
observed here. This suggests physiological variability, where other factors affect 
the threshold for CSD and glucose derangement. As an example, we have 
observed the large range of incidence of CSD across cohorts: 38% to 90%, 
suggesting large individual variation in susceptibility (though it is noteworthy that 
this may be influenced by injury subtype, not accounted for here). 
 
Broader limitations: 
There are wider issues rendering the study of the relationship between glucose 
and CSD difficult to understand. These relate primarily to the available methods 
for observing both CSD and glucose concentrations. CSD is a focal phenomenon, 
 
 
and CMD catheters capture glucose concentration from a focal region; it is likely 
that for a significant number of CSD events, the point of CSD origin is not at the 
point of microdialysis monitoring. Global cerebral glycopenia would be detected 
to coincide with CSD events, resulting in positive findings. However, discrete 
areas of cerebral glycopenia triggering CSD away from the microdialysis catheter 
would go undetected. This is an important limitation in the current methodology, 
which arguably increases the likelihood of negative findings in such studies. 
This is further dependent on the location of the probes. Pinczolits et al30 identified 
an effect of clustered CSD on glucose only at the CMD probe 5mm from the 
infarct rim, and not at 15mm. This suggests that glucose fall in response to CSD 
is highly localised. 
Given the transient and localised nature of the glucose fall after CSD, studies 
utilising intermittent sampling have not detected significant change. This is with 
one key exception – where recurrent episodes elicit a more profound and lasting 
effect on glucose, this change becomes amenable to detection through low-
resolution sampling. This amenability to observation is also dependent on CMD 
probes being positioned sufficiently proximate to the area of neural tissue 
depolarising, evidenced by differing results based on proximity.30 However, due 
to insufficient precision in placement and its reporting across the included studies, 
 
 
it is difficult to draw meaningful conclusions regarding negative findings and 
subdural grid/microdialysis catheter proximity.  
The proximity of CSD and CMD has been discussed, but also of relevance is the 
proximity of both to the injury. Where located in tissue which is not subject to the 
same metabolic strains of the injury core, it is probable that the glucose decrease 
after CSD would be less profound. As such, findings here may not reflect the 
relationship between CSD and glucose in tissue affected by injury. Further 
discussion on this as a limitation in the study of CSD has been comprehensively 
reviewed elsewhere.2,42  
 
Future directions: 
Whilst we have offered tentative conclusions based on the studies and results 
included in this review, the evidence offered is inconsistent. As described this is 
likely in part due to methodological differences. Collaborative efforts could 
facilitate prospective and homogenous analysis of such data on a larger scale, 
likely resulting in a greater consistency in evidence. Furthermore, we have 
discussed the effect of serum glucose on CSD incidence, and two studies 
associated serum glucose derangement with CSD probability.25,32 Applying the 
principle of increasing temporal resolution to improve validity, the investigation of 
 
 
serum glucose would also benefit from the utilisation of continuous monitoring 
paradigms. This could elucidate the cause-effect nature of deranged serum 
glucose and CSD probability by temporally resolving which occurs first. Similarly 
for CMD: the dynamics clearly occur predominantly in short temporal windows: 
the high resolution offered by rsMD for its study is far superior to intermittent 
sampling. Future studies should utilise this technique where available.  
The area of most tentative evidence in this review is in the recursive relationship: 
with both glucose derangement and CSD being both cause and effect. 
Investigating this will require high resolution studies with close temporal analysis. 
Furthermore, CSD propensity is more complex than a dependence on glucose 
alone. High resolution, multimodal monitoring with multivariate logistic regression 
could elaborate on the spectrum predictor variables of CSD, and their respective 
significance and interaction. 
Considering the above discussion, specifically, we propose the ideal 
characteristics of future studies: 
1. High resolution sampling, with temporally resolved analysis to consider 
glucose preceding and following CSD. 
 
 
2. Consistent and close proximity of subdural electrode grid and 
microdialysis catheter, with confirmation of proximity with post-operative 
imaging. 
3. Consistent relationship between subdural electrode and pathological 
entity, i.e. ischaemic penumbra or peri-contusional tissue. 
4. Measurement and reporting of potential confounding factors: systemic 
glucose, cerebral perfusion pressure (as a surrogate of cerebral blood 
flow), and brain tissue oxygen. 
5. In addition to simple correlation measures observed in these studies, 
specific analysis based on thresholds of cerebral glucose (e.g. <0.2 or <0.5 
mmol/L) as potential precipitants, as a more efficient analysis of what 
would constitute a clinically significant level of extracellular glycopenia. 
6. Prospectively defined, or retrospectively categorised, pathology for 
inclusion, to avoid confounding factors or variability as a result of differing 
cellular pathology which may result in subtle relational differences 
affecting validity of results. 
7. Recording and nominal analysis of extracellular lactate. 
8. Recording of plasma glucose with examination of the inter-relationship 
with cerebral extracellular glucose in the context of CSD. 
 
 
 
Conclusions: 
This systematic review has collated the evidence of the dynamics of glucose and 
its relationship to CSD in brain injury. The identified studies were heterogeneous 
in their methodology with inconsistent results, though the majority have identified 
a correlation. There is good evidence that CSD leads to a fall in local cerebral 
glucose, with evidence that this may be prolonged. There is minimal evidence 
that deranged glucose may provoke further CSD (likely dependent on other 
factors), which in turn can lead to progressive glucose depletion. Given the strong 
correlation between CSD and glucose, a cyclical relationship is possible. Further 
study, utilising high resolution techniques, would be required to confirm this 
proposed relationship, specifically examining deranged glucose as a predictor of 
CSD. Serum glucose, and how this inter-relates with CSD and cerebral glucose, 
is of clear relevance but to date has received little consideration. With further 
understanding of these important relationships, the incidence of CSD could be 
addressed by therapeutic intervention targeted at systemic and cerebral glucose 
control. 
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Appendix 1. 
 
The following example search strategy is taken from our search of Embase: 
1. exp spreading cortical depression/ 
2. cortical spreading depression.mp 
3. spreading depolarisation.mp 
 
 
4. spreading depolarization.mp 
5. spreading depression.mp 
6. 1 or 2 or 3 or 4 or 5 
7. exp glucose/  
8. glucose.mp 
9. hyperglycaemia.mp 
10. exp hyperglycemia/ 
11. hypoglycaemia.mp 
12. exp hypoglycemia/ 
13. exp brain metabolism/ 
14. exp energy metabolism/ 
15. exp glucose metabolism/ 
16. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
17. exp traumatic brain injury/ 
18. traumatic brain injury.mp 
19. exp head injury/ 
20. exp brain injury/ 
21. exp cerebrovascular accident/ 
22. stroke.mp 
23. exp brain hemorrhage/ 
24. intracerebral haemorrhage.mp 
25. exp subarachnoid hemorrhage/ 
26. subarachnoid haemorrhage.mp 
27. intracranial haemorrhage.mp 
 
 
27. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 
27. 6 and 16 and 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2. 
 
Extracellular glucose and plasma glucose in CSD 
The relationship between extracellular glucose and plasma glucose in the context 
of CSD has largely been unexamined in the included studies, despite recording 
 
 
of both variables. Krajewski et al25 used both cerebral and plasma glucose in their 
Spearman’s correlation analysis with CSD, though did not examine the inter-
relationship between the two. Rogers et al27 recorded one episode where 
extracellular glucose was low (100µM), despite plasma glucose being high 
(11.8mM), but conducted no further analysis regarding this relationship. In the 
supplementary material for Feuerstein et al43 – linear regression demonstrated 
poor correlation between plasma glucose and rsMD glucose through linear 
regression completed for the six non-diabetic patients with full data available (R2 
values range 0.01-0.40).  
Two studies sought to correlate plasma glucose with incidence of CSD. Hocker 
et al32 in their abstract observed CSD probability rising as a function of increased 
serum glucose (p<8x10-6), but did not record CMD glucose values. It is 
noteworthy that this work was not subject to peer review. Krajewski et al25 showed 
that periods of deranged serum glucose partially correlated with increased 
frequency of CSD (hyperglycaemia r=0.464, p<0.05) (hypoglycaemia r=0.485, 
p<0.05). Despite the clinical importance of the relationship between serum 
glucose, cerebral glucose and CSD, there is a clear paucity of data, with 
insufficient consideration of all three variables to draw conclusions on the efficacy 
of modulating serum and cerebral glucose as a means to reduce incidence of 
CSD. 
 
 
Considering the interesting observations of inverse plasma-cerebral glucose 
relationships, and a strong correlation between plasma hyperglycaemia and 
CSD, this inter-relationship is worthy of further exploration. This is of particular 
importance when considering clinical intervention to increase plasma glucose 
with the therapeutic aim of averting cerebral glycopenia. If the relationship is 
altered or inverted in some instances of CSD, such as observed by Rogers et 
al,27 such intervention may be of little value in increasing cerebral glucose. 
Further, inducing plasma hyperglycaemia in such instances may have a 
secondary effect of paradoxically increasing CSD propensity as suggested by 
Hocker et al.32 Further investigation is required to ascertain the values and risks 
of these clinical scenarios. 
 
 
 
 
 
 
Appendix 3. 
 
Lactate as an alternative metabolic substrate 
The metabolic “signature” discussed across included articles is considered as a 
phenomenon of a transient decrease in cerebral glucose accompanied by a 
 
 
transient increase in lactate. However, there is growing recognition of the role of 
lactate as an alternative substrate for metabolism, particularly post-TBI.44 Recent 
microdialysis evidence in the rat model has produced a hypothesised threshold 
lactate level of >80% above normal, beyond which neurons will utilise lactate as 
a substrate.43  
In the included studies, though cerebral lactate has been measured alongside 
glucose, the analysis has been directed toward recognition of lactate increase as 
a result of classical anaerobic metabolism of glucose during the high metabolic 
demand subsequent to CSD. There has been little exploration of lactate 
decrease. Parkin et al26 have observed transient decreases in lactate around 
CSD, but have not reported specific evaluation of this phenomenon relative to the 
baseline lactate level, nor attempts at correlation with low glucose availability at 
these time points. 
Hartings et al23 recorded an interval of 10 hours with brain glucose <0.1mmol/L. 
During this time, 11 CSD occurred, with lactate and lactate/pyruvate ratio (LPR) 
both elevated throughout (3-7mmol/L and >40 respectively), with no indication of 
utilisation of lactate as a substrate. Concomitantly however, PtiO2 during this 
interval was 8-10mmHg (a fall from >20mmHg) and CPP was not reported, so it 
is unclear whether these conditions are entirely dependent on metabolic 
substrate factors alone, or wider physiological variables such as CBF and oxygen 
 
 
availability. At a later interval, with cerebral glucose <0.10mmol/L, 20 CSD 
occurred – during this time LPR rose above 40 (lactate concentration not 
reported). 
Krajewski et al25 examined lactate values as a dichotomous variable – either 
“pathological” (>4mM) or normal. Based on this analysis, they observed a 
“marked improvement” of lactate concentrations for one hour after CSD (i.e. 
decreased incidence of extracellular lactate >4mM). With some conjecture, this 
could indicate utilisation of lactate as a substrate in the relative absence of 
glucose, though equally this phenomenon could be explained by, for example, 
reactive hyperaemia leading to increased lactate extraction from local tissue. 
Without dynamic, time-resolved, nominal lactate data collection and analysis, 
these types of studies would be unable to elucidate the role of lactate as a 
substrate, particularly in the contexts of high lactate or low glucose availability. 
 
